Baowei Zhao

USPTO Granted Patents = 10 (Patent Applications = 8)

EPO Patents = 4 (Patent Applications = 17)

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

4 out of 230

Glaxosmithkline Intellectual Property Development Limited

patents

4 out of 10

Abbisko Therapeutics Co., Ltd

Years Active: 2012-2025

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12473282 - Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof (2025-11-18),

2. 11180495 - Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof (2021-11-23),

3. 11149021 - N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof (2021-10-19),

4. 11130762 - Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy (2021-09-28),

5. 11034696 - Compounds for inhibiting LRRK2 kinase activity (2021-06-15),

6. 10975081 - Substituted fused pyrazole compounds and their use as LRRK2 inhibitors (2021-04-13),

7. 10858367 - Compounds (2020-12-08),

8. 10618901 - LRRK2 inhibitors for the treatment of Parkinson's disease (2020-04-14),

9. 8389508 - Heterocyclic compounds (2013-03-05),

10. 8217028 - 1,2,4-oxadiazole indole compounds (2012-07-10),

Title: Celebrating the Innovations of Inventor Baowei Zhao

Introduction: Baowei Zhao, an accomplished inventor based in Shanghai, China, has made significant contributions to the field of pharmaceutical research. With a portfolio of nine patents, his work focuses on innovative compounds that hold promise for treating a variety of serious health conditions, including various types of cancer and autoimmune diseases.

Latest Patents: Baowei Zhao's latest advancements include two notable patents. The first patent details a nitrogen heteroaryl derivative that exhibits CSF1R inhibitory activity, along with its preparation method and potential applications. This compound is particularly relevant for the development of drugs targeting conditions such as ovarian cancer, pancreatic cancer, and other serious diseases. The second patent revolves around an N-(azaaryl)cyclolactam-1-carboxamide derivative, which also shows potential as a CSF-1R inhibitor. This derivative aims to empower the fight against similar diseases through innovative drug formulations.

Career Highlights: Throughout his career, Baowei Zhao has collaborated with prominent companies such as GlaxoSmithKline Intellectual Property Development Limited and Abbisko Therapeutics Co., Ltd. His expertise and contributions have been instrumental in advancing pharmaceutical research and contributing to the innovation landscape.

Collaborations: Baowei Zhao has worked alongside notable colleagues, including Feng Ren and Yingxia Sang. These collaborations have fostered an environment of innovation and have played a pivotal role in the development of impactful healthcare solutions.

Conclusion: As a leading inventor in the pharmaceutical arena, Baowei Zhao continues to push the boundaries of drug development through his extensive research and patented innovations. His work not only reflects his commitment to advancing medical science but also highlights the potential for creating new treatments that address critical health issues.

This text is generated by artificial intelligence and may not be accurate.